-
Galunisertib (LY2157299) is a
small molecular experimental cancer drug
previously in
development by Eli Lilly. It is a TGF-b inhibitor.
Development of...
- and thus
apoptosis as seen in the left
panel of the
adjacent image.
Galunisertib is the
selective and
potent TGFβRI
kinase inhibitor. The
parasitic roundworm...
-
Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761
Galunisertib (LY-2157299) R-268712
RepSox (E-616452, SJN-2511) SB-431542 SB-505124...
-
being developed by
Senhwa Biosciences.
Another small molecule inhibitor Galunisertib (LY2157299) is a
potent TGF-β type I
receptor kinase inhibitor that was...
- PPP2R2A, STRAP, TGF beta 1, and TGF beta
receptor 2. GW-788388 LY-2109761
Galunisertib (LY-2157299) SB-431542 SB-525334
RepSox Defects are
observed when the...
- well-characterised polymorphs, with its
nearest competitors being aripiprazole and
galunisertib. The
various crystal forms display alternative conformers, a type of...
-
Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761
Galunisertib (LY-2157299) R-268712
RepSox (E-616452, SJN-2511) SB-431542 SB-505124...
-
Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761
Galunisertib (LY-2157299) R-268712
RepSox (E-616452, SJN-2511) SB-431542 SB-505124...
-
Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761
Galunisertib (LY-2157299) R-268712
RepSox (E-616452, SJN-2511) SB-431542 SB-505124...
- ****ociated with
Chagas disease), and
potential antiviral properties.
Galunisertib LY-2109761
Gellibert F, de
Gouville AC,
Woolven J,
Mathews N, Nguyen...
